Indicators of bone metabolism in patients of psychiatric clinic on the background of dimephosphone intake
- Authors: Il’ina RY.1, Pasynkova OO2, Mukhamedzhanova LR3, Ziganshina LE4
-
Affiliations:
- Kazan State Medical Academy
- Republican Clinical Hospital of War Veterans of the Republic of Mari El
- Chuvash State University named after I.N. Ulyanov
- Kazan (Volga Region) Federal University
- Issue: Vol 97, No 5 (2016)
- Pages: 669-673
- Section: Theoretical and clinical medicine
- URL: https://kazanmedjournal.ru/kazanmedj/article/view/5558
- DOI: https://doi.org/10.17750/KMJ2016-669
- ID: 5558
Cite item
Full Text
Abstract
Aim. To study the indicators of bone metabolism in patients of psychiatric clinics on the background of dimephosphone oral intake.
Methods. Research was conducted at the Republican Clinical Psychiatric Hospital named after V.M. Bekhterev (Kazan). 64 patients (36 men and 28 women) aged 45 to 68 years (mean age 56.8±6.9 years) with various forms of mental disorders taking psychotropic drugs for the period of 3 years and over were examined. Resorption markers were determined - D-pyridinoline in urine, serum tartrate-resistant acid phosphatase, alkaline phosphatase, and the content of total and ionized serum calcium. All patients were divided into two groups: those who received dimephosphone in the combined systemic therapy and those who did not. The average duration of the dimephosphone administration was 22±4.2 days, the patients undergone on average 2.6±1.44 courses of treatment during 6 months.
Results. The activity of tartrate-resistant acid phosphatase in psychiatric patients was higher compared with those of the control group. The maximum value was registered in patients who were not taking dimephosphone. The alkaline phosphatase activity was the highest in mentally healthy patients of the control group. In psychiatric patients treated with dimephosphone, alkaline phosphatase activity was 20% lower compared with the control group. The minimum values of alkaline phosphatase were registered in patients with mental disorders not taking dimephosphone. When studying the concentration of total and ionized serum calcium there were no significant differences between patients of comparison group and psychiatric patients.
Conclusion. Shift in processes of bone remodeling toward its resorption indicates a high risk of pathological fractures in psychiatric patients and the need for osteoporosis prevention; identified changes in biochemical markers of osteoporosis on the background of dimephosphone intake allow to recommend it for the treatment of diagnosed osteoporosis in a psychiatric hospital settings.
Keywords
About the authors
R Yu Il’ina
Kazan State Medical Academy
Author for correspondence.
Email: ilroza@yandex.ru
O O Pasynkova
Republican Clinical Hospital of War Veterans of the Republic of Mari El
Email: ilroza@yandex.ru
L R Mukhamedzhanova
Chuvash State University named after I.N. Ulyanov
Email: ilroza@yandex.ru
L E Ziganshina
Kazan (Volga Region) Federal University
Email: ilroza@yandex.ru
References
- Валеева И.Х., Титаренко А.Ф., Хазиахметова В.Н., Зиганшина Л.Е. Димефосфон проявляет противовоспалительную и антиоксидантную активность на модели хронического аутоиммунного воспаления. Эксперим. и клин. фармакол. 2008; 74 (3): 13-16.
- Зиганшина Л.Е., Бурнашева З.А., Валеева И.Х. и др. Сравнительная оценка эффективности димефосфона и ксидифона при моделировании стероидного остеопороза у крыс. Эксперим. и клин. фармакол. 2000; 63 (6): 39-42.
- Ильина Р.Ю., Зиганшина Л.Е. Анализ осложнений травматических переломов у психически больных. Практич. мед. 2013; (1-2): 59-62.
- Ильина Р.Ю., Зиганшина Л.Е., Мухамеджанова Л.Р., Гурьянова Т.В. Переломы костей у психически больных (ретроспективный анализ историй болезни с 1996 по 2010 г.). Практич. мед. 2012; (8-2): 81-86.
- Малышев В.Г., Федосейкин И.В. Применение димефосфона в медицине. М.: Наука. 2008; 84-85.
- Насонов Е.Л. Проблемы остеопороза: изучение биохимических маркёров костного метаболизма. Клин. мед. 1998; (5): 20-25.
- Abel K.M., Heatlie H.F., Howard L.M., Webb R.T. Sex- and age-specific incidence of fractures in mental illness: a historical, population-based cohort study. J. Clin. Psychiatry. 2008; 69 (9): 1398-1403. http://dx.doi.org/10.4088/JCP.v69n0907
- Hummer M.P., Malik W. Rudolf, Gasser M.D. et al. Osteoporosis in patients with schizophrenia. Am. J. Psychiatry. 2005; (162): 162-167. http://dx.doi.org/10.1176/appi.ajp.162.1.162
- Ilina R.J., Pasynkova O., Ziganshina L.E. Predicting and managing adverse reactions of psychotropic drugs. Intern. J. Risk and Safety in Med. 2013; (25): 95-103. http://dx.doi.org/10.3233/JRS-130584
- Meyer J.M., Lehman D. Bone mineral density in male schizophrenia patients: a review. Ann. Clin. Psychiatry. 2006; 18 (1): 43-48. http://dx.doi.org/10.1080/10401230500464687
- O’Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. Psychopharmacol. 2008; (22): 70-76. http://dx.doi.org/10.1177/0269881107088439
- Perreault S., Dragomir A., Moride Y. et al. Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture. Pharmacoepidemiol. Drug Saf. 2008; 17 (3): 248-259. http://dx.doi.org/10.1002/pds.1551
- Takkouche B., Montes-Martinez A., Gill S.S., Etminan M. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf. 2007; 30 (2): 171-184. http://dx.doi.org/10.2165/00002018-200730020-00006